Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)

Trial Profile

Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Sep 2013.
    • 28 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2013.
    • 23 Sep 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top